Esophageal Cancer Market Size & Share, by Type (Esophageal Squamous-Cell Carcinoma, Esophageal Adenocarcinoma); Phase; Treatment - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

North America Market Analysis

North America esophageal cancer market is set to capture over 25.7% revenue share by 2037. The increased healthcare expenditure and additional regulatory approvals have remarkably helped the region maximize access to adequate cancer care facilities. In addition, the high occurrence of ECs across this regional demography ensured an uninterrupted flow of innovations in this sector, backed by national health organizations and pharma leaders. According to the National Cancer Institute, around 22,370 citizens of America are poised to get diagnosed with esophageal cancer, whereas, the number of death cases is estimated to account for 16,130 in 2024. The report further evaluated the new cases to reach 17,690 in men and 4,680 in women in the same year.

The U.S. is augmenting the esophageal cancer market with a higher prevalence rate of esophageal adenocarcinoma compared to other landscapes. This has cultivated a good supply-demand chain in this sector, empowered by the presence of globally leading pharmaceutical companies. Thus, the country is considered to be at the top of the list of profitable marketplaces across the world. According to the National Library of Medicine, the accumulated expenditure value of immune checkpoint inhibitors (ICIs) in the U.S. reached USD 4.1 billion in 2021. On the other hand, the cost per prescription dropped by USD 20881.1 between 2011 and 2021. This shows the meticulous efforts of the country in making treatment more generally available for patients.  

Canada is opening new opportunities for global leaders in the esophageal cancer market by deliberately pushing the government to take immediate action against the rising EC and mortality cases. The country’s governing authorities are well aware of the concerning statistics of probable new and death cases, which is forcing them to adopt effective strategies such as research funding and accelerated drug approvals. For instance, in January 2025, Health Canada accepted the application for commercialization of the FDA-approved VYLOY (zolbetuximab for injection) by Astellas Pharma. This ensured sufficient distribution of this VYLOY, which is highly effective for advanced gastric and gastroesophageal junction cancer when combined with chemotherapy.

APAC Market Statistics

Asia Pacific is projected to witness the fastest growth in the esophageal cancer market during the period, 2025-2037. The frequent incidences and higher mortality cases of ECs across the region are notable driving factors in this sector. The share of incidence and mortality of esophageal cancer in Asia was accounted to be the highest in the world by 2020, capturing 79.7% and 79.8% respectively, as per NLM data. Developing countries such as India, China, and Japan are utilizing their pharmaceutical excellence to cope with the rising threats to public health. Their governing bodies are also participating in these initiatives by offering ease of trading for both domestic and international leaders of this sector.

EC Incidence & Mortality Cases in APAC Countries (2020):

China, with its enhanced R&D capabilities, distributed along with pharma companies and several research institutions is commendably solidifying its grasp on the esophageal cancer market. The country’s notable progress in the biopharmaceutical industry has paid off in its continuous investments in clinical trials and drug developments. This brought new treatment solutions from their collection of innovative therapeutics with promising results. For instance, in May 2024, Mabwell gained an Orphan Drug Designation (ODD) from the FDA for its solely developed Nectin-4-targeting ADC. This novel therapy paved the way for the expansion of the company in the U.S. EC market. 

The emphasizing pharma industry of India is presenting prosperous opportunities for the esophageal cancer market. With the rise in the conjugated value of imports and exports in the country, international forces are finding lucrative scopes of investment in this sector. According to IBEF data, the pharmaceutical industry of India is anticipated to be valued at USD 130.0 billion by 2030 due to the inflating demand for innovative therapies. In addition, the country’s bioeconomy is projected to hold USD 300.0 billion by the same timeframe, making it the 3^rd largest shareholder of the Asia biotechnology industry. This signifies the potential of this country to make remarkable progress in this sector.